Association between low-dose folic acid supplementation and blood lipids concentrations in male and female subjects with atherosclerosis risk factors

Background Folic acid (FA) is one of the B complex vitamins. It is thought that FA deficiency promotes atherosclerosis formation in arterial endothelium. FA, acting through reducing homocysteine (Hcy) levels, may contribute to decreased cholesterol (Ch) synthesis. The aim of this study was to analyze the association of low-dose folic acid supplementation with blood lipids concentrations in subjects with atherosclerosis risk factors. Material/Methods The study enrolled 124 Caucasian individuals (60 M, ages 20–39; and 64 F, ages 19–39) with atherosclerosis risk factors (family history of premature ischemic stroke, arterial hypertension, dyslipidemia, overweight and obesity, cigarette smoking, and low level of physical activity). The participants were asked to take FA at a low dose of 0.4 mg/24 h for 12 weeks. Results FA levels increased in females (6.3 vs. 12.5 ng/dL; p=0.001) and males (6.4 vs. 11.4 ng/dL; p=0.001) and Hcy levels decreased (10.6 vs. 8.3 μmol/L; p=0.001 and 11.5 vs. 9.3; p=0.001, respectively). A significant reduction in mean concentration of total cholesterol in females (203.4 vs. 193.1 mg/dL; p=0.001) and in males (209.5 vs. 201.9; p=0.002) was observed. The low-density lipoprotein cholesterol (LDL-C) levels decreased in females and in males (107.4 vs. 99.9 mg/dL; p=0.001 and 121.5 vs. 115.1; p=0.002, respectively). The apoAI concentrations increased in smoking women and in men with BMI ≥25 kg/m2 (p=0.032 and p=0.024, respectively). Conclusions Low-dose FA supplementation has a beneficial effect on blood lipids through decreasing concentrations of total cholesterol and LDL-C and increasing concentrations of apoAI.

[1]  M. Naruszewicz,et al.  Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. , 2001, Metabolism: clinical and experimental.

[2]  I. Blair,et al.  Mild folate deficiency induces a proatherosclerotic phenotype in endothelial cells. , 2006, Atherosclerosis.

[3]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[4]  G. Kade,et al.  Albuminuria and hyperhomocysteinemia as cardiovascular risk factors in potentially healthy soldiers: A long-term observation , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[5]  M. K. Garg,et al.  Vitamin B12 deficiency and hyperhomocysteinemia as correlates of cardiovascular risk factors in Indian subjects with coronary artery disease. , 2013, Journal of cardiology.

[6]  H. McNulty,et al.  A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. , 2011, The American journal of clinical nutrition.

[7]  R. Rozen,et al.  Elevated Homocysteine Reduces Apolipoprotein A-I Expression in Hyperhomocysteinemic Mice and in Males With Coronary Artery Disease , 2006, Circulation research.

[8]  R. Collins,et al.  Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. , 2007, American heart journal.

[9]  Joseph Loscalzo,et al.  Homocysteine trials--clear outcomes for complex reasons. , 2006, The New England journal of medicine.

[10]  C. Iden,et al.  Homocysteine Induces 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase in Vascular Endothelial Cells: A Mechanism for Development of Atherosclerosis? , 2002, Circulation.

[11]  C. Stefanadis,et al.  Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. , 2008, European heart journal.

[12]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[13]  V. Thijs,et al.  Lipoprotein (a) and Stroke: A Meta-Analysis of Observational Studies , 2007, Stroke.

[14]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[15]  Arif Ali,et al.  Lowering homocysteine and modifying nutritional status with folic acid and vitamin B12 in Indian patients of vascular disease , 2012, Journal of clinical biochemistry and nutrition.

[16]  D. Sprecher,et al.  Fiber-multivitamin combination therapy: a beneficial influence on low-density lipoprotein and homocysteine. , 2002, Metabolism: clinical and experimental.

[17]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[18]  W. Aronow,et al.  The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice , 2012, Archives of medical science : AMS.

[19]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[20]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[21]  P. Wilson,et al.  Lipoprotein(a) and coronary heart disease. , 1994, Chemistry and physics of lipids.

[22]  R. Mayeux,et al.  Higher folate intake is related to lower risk of Alzheimer’s disease in the elderly , 2008, The journal of nutrition, health & aging.

[23]  Shufeng Zhou,et al.  Knowledge and use of folic acid for birth defect prevention among women of childbearing age in Shanghai, China: A prospective cross-sectional study , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[24]  A. A. Liakishev [Homocysteine lowering with folic acid and B vitamins in vascular disease]. , 2006, Kardiologiia.